BCAX (Bicara Therapeutics) Debt-to-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Debt-to-Asset?

Bicara Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.59 Mil. Bicara Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil. Bicara Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was $478.08 Mil. Bicara Therapeutics's debt to asset for the quarter that ended in Mar. 2025 was 0.00.

Bicara Therapeutics Debt-to-Asset Historical Data

The historical data trend for Bicara Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Debt-to-Asset Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-Asset

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Bicara Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Bicara Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Bicara Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bicara Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.607	+	0.131)	/	509.996
	=	0.00

Bicara Therapeutics's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.591	+	0)	/	478.077
	=	0.00

Bicara Therapeutics (NAS:BCAX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bicara Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.